C-Met in invasive breast cancer
Is there a relationship with the basal-like subtype?
Article first published online: 21 OCT 2013
© 2013 American Cancer Society
Volume 120, Issue 2, pages 163–171, 15 January 2014
How to Cite
Ho-Yen, C. M., Green, A. R., Rakha, E. A., Brentnall, A. R., Ellis, I. O., Kermorgant, S. and Jones, J. L. (2014), C-Met in invasive breast cancer. Cancer, 120: 163–171. doi: 10.1002/cncr.28386
- Issue published online: 7 JAN 2014
- Article first published online: 21 OCT 2013
- Manuscript Accepted: 20 AUG 2013
- Manuscript Revised: 5 AUG 2013
- Manuscript Received: 8 JUL 2013
- breast cancer;
- triple negative;
Basal-like (BL) breast cancer is an aggressive form of breast cancer with limited treatment options. Recent work has identified BL breast cancer as a biologically distinct form of triple-negative breast cancer, with a worse outlook. The receptor tyrosine kinase c-Met is a novel therapeutic target associated with reduced survival in breast cancer. Few studies have specifically addressed the association between c-Met and molecular subtype of breast cancer, yet this is a key consideration when selecting patients for clinical trials. The aim of this study is to evaluate c-Met expression in a large cohort of invasive breast cancers and in particular, its correlation with molecular subtype.
Immunohistochemistry for c-Met was performed and evaluated on 1274 invasive breast cancers using tissue microarray technology. The c-Met scores were correlated with molecular subtype, survival, and other standard clinicopathological prognostic factors.
Multivariate logistic regression showed c-Met was independently associated with BL status (odds ratio = 6.44, 95% confidence interval = 1.74-23.78, P = .005). There was a positive correlation between c-Met and Her2 (P = .005) and an inverse correlation with tumor size (P < .001). C-Met was an independent poor prognostic factor at Cox regression analysis in all subtypes (hazard ratio = 1.85, 95% confidence interval = 1.07-3.19, P = .027) and there was a trend toward reduced survival in BL tumors overexpressing c-Met, but this was not significant.
C-Met is independently associated with BL breast cancer. In the future, patients with BL tumors should be included in clinical trials of anti-c-Met therapy. Cancer 2014;120:163–171. © 2013 American Cancer Society.